Autres langues Foghorn Therapeutics Inc.

Actions

FHTX

US3441741077

Marché Fermé - Nasdaq Autres places de cotation 19:00:00 03/07/2024			Varia. 5j.	Varia. 1 janv.
5,62 ^USD	+3,31 %		-2,09 %	-12,87 %

20/05	Foghorn Therapeutics fixe le prix d'une offre d'actions et de bons de souscription préfinancés d'un montant de 110 millions de dollars	MT
06/05	Foghorn Therapeutics Inc. annonce ses résultats pour le premier trimestre clos le 31 mars 2024	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Foghorn Therapeutics Inc.(NasdaqGM:FHTX) added to Russell Small Cap Comp Value Index	01/07
Foghorn Therapeutics Inc.(NasdaqGM:FHTX) added to Russell 3000 Value Index	01/07
Foghorn Therapeutics Inc.(NasdaqGM:FHTX) added to Russell 2500 Value Index	01/07
Foghorn Therapeutics Inc.(NasdaqGM:FHTX) added to Russell 2000 Value Index	01/07
Foghorn Therapeutics Inc.(NasdaqGM:FHTX) added to Russell Microcap Value Index	01/07
Foghorn Therapeutics Inc.(NasdaqGM:FHTX) added to Russell 3000E Value Index	01/07
Flagship Pioneering and ProFound Therapeutics Announce Agreement to Identify Novel First-in-Class Therapeutics for the Treatment of Obesity under Strategic Partnership with Pfizer	13/06
Foghorn Therapeutics to Participate in Upcoming Investor Conferences in June	28/05
Foghorn Therapeutics Raises Approximately $110 Million Through Registered Direct Offering to Advance Pipeline	23/05
Foghorn Therapeutics Raises Approximately $110 Million Through Registered Direct Offering to Advance Pipeline	23/05
Foghorn Therapeutics Prices $110 Million Offering of Shares, Pre-Funded Warrants	20/05
Foghorn Announces Pricing of Registered Direct Offering of Common Stock and Pre-Funded Warrants	20/05
Foghorn Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	06/05
Foghorn Therapeutics Provides First Quarter 2024 Financial and Corporate Update	06/05
Foghorn Therapeutics Provides First Quarter 2024 Financial and Corporate Update	06/05
North American Morning Briefing : Stock Futures -2-	06/05
Foghorn Therapeutics Names Kristian Humer CFO	16/04
Foghorn Therapeutics Strengthens Financial Leadership with Appointment of Kristian Humer as Chief Financial Officer	16/04
Foghorn Therapeutics Inc. Appoints Kristian Humer as Chief Financial Officer	16/04
Foghorn Therapeutics Presents New Preclinical Data on Potential First-in-Class BRM Selective Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Oncology Programs	09/04

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Foghorn Therapeutics Inc.

Actions

FHTX

US3441741077

Autres langues

Filtres